Altorki Nasser K, Lee Paul C, Liss Yaakov, Meherally Danish, Korst Robert J, Christos Paul, Mazumdar Madhu, Port Jeffrey L
Division of Thoracic Surgery, Department of Cardiothoracic Surgery, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA.
Ann Surg. 2008 Mar;247(3):434-9. doi: 10.1097/SLA.0b013e318163a2ff.
There has been an increase in interest in endoscopic therapy (ET) for intramucosal (T1a) or submucosal (T1b) esophageal carcinoma. The objective of the present study was to determine the prevalence of nodal metastases, lymphatic vascular invasion, and multifocal neoplasia in patients with pT1 esophageal carcinoma who underwent esophagectomy without preoperative therapy and assess their potential implication for ET.
We retrospectively reviewed the records of all patients who underwent esophagectomy without preoperative therapy for pT1 esophageal cancer. A detailed review of all pathology reports was performed to identify relevant pathologic criteria including depth of invasion (T1a or T1b), cell type (adenocarcinoma/squamous), tumor differentiation (poor vs. well/moderate), extent of Barrett esophagus (short segment [SSBE] and long segment [LSBE]), nodal status, lymphovascular invasion (LVI), and the presence of multifocal neoplasia (MFN) (high-grade dysplasia or invasive carcinoma). Overall survival and disease-specific survival were determined by the Kaplan-Meier method.
There were 75 consecutive patients (58 men, 17 women) between January 1994 and September 2006. Median age was 68 years. Hospital mortality was 2.6% (2 of 75). Thirty patients had T1a and 45 had T1b. Sixty patients had adenocarcinoma. Nodal metastases were present in 2 of 30 (6%) T1a and 8 of 45 (17.5%) T1b tumors. MFN was present in 30% (9 of 30) of T1a tumors and 29% (13 of 45) of T1b tumors. All 9 patients with LVI had T1b tumors. Collectively, 10 of 30 (33.3%) patients with T1a and 25 of 45 (58%) with T1b had MFN, LVI, or nodal metastases. Forty-nine patients had adenocarcinoma with associated BE (23 SSBE, 26 LSBE). There was no difference between patients with SSBE and those with LSBE in the incidence of nodal disease (2 of 23 vs. 2 of 26) but a significant difference in the incidence of MFN (3 of 23 vs. 13 of 26, P = 0.006). Four patients with squamous carcinoma had nodal metastases and 5 had MFN. Overall 5-year survival was 78% (T1a:90% T1b: 71%, P = 0.07). Five-year disease-specific survival was 86.5% (T1a: 96.7%, T1b: 79.6%, P = 0.06).
The combined high incidence of MFN, LVI, and occult nodal metastases does not support the use of ET in patients with T1 esophageal cancer regardless of depth of invasion, cell type, differentiation or extent of BE. ET may be of value in patients in whom surgical risk is considered prohibitive.
对于黏膜内(T1a)或黏膜下(T1b)食管癌的内镜治疗(ET),人们的兴趣日益增加。本研究的目的是确定接受了无术前治疗的食管切除术的pT1期食管癌患者的淋巴结转移、淋巴管侵犯及多灶性肿瘤形成的发生率,并评估它们对ET的潜在影响。
我们回顾性分析了所有接受无术前治疗的pT1期食管癌食管切除术患者的记录。对所有病理报告进行了详细审查,以确定相关病理标准,包括浸润深度(T1a或T1b)、细胞类型(腺癌/鳞癌)、肿瘤分化程度(低分化与高分化/中分化)、巴雷特食管范围(短节段[SSBE]和长节段[LSBE])、淋巴结状态、淋巴管侵犯(LVI)以及多灶性肿瘤形成(MFN)(高级别异型增生或浸润性癌)的存在情况。采用Kaplan-Meier法确定总生存期和疾病特异性生存期。
1994年1月至2006年9月期间,连续纳入75例患者(58例男性,17例女性)。中位年龄为68岁。医院死亡率为2.6%(75例中的2例)。30例患者为T1a期,45例为T1b期。60例患者为腺癌。30例T1a期肿瘤中有2例(6%)出现淋巴结转移,45例T1b期肿瘤中有8例(17.5%)出现淋巴结转移。30%(30例中的9例)的T1a期肿瘤和29%(45例中的13例)的T1b期肿瘤存在MFN。所有9例发生LVI的患者均为T1b期肿瘤。总体而言,30例T1a期患者中有10例(33.3%)、45例T1b期患者中有25例(58%)存在MFN、LVI或淋巴结转移。49例腺癌患者伴有BE(23例SSBE,26例LSBE)。SSBE患者和LSBE患者在淋巴结疾病发生率方面无差异(23例中的2例对26例中的2例),但在MFN发生率方面存在显著差异(23例中的3例对26例中的13例,P = 0.006)。4例鳞癌患者出现淋巴结转移,5例存在MFN。总体5年生存率为78%(T1a期:90%,T1b期:71%,P = 0.07)。5年疾病特异性生存率为86.5%(T1a期:96.7%,T1b期:79.6%,P = 0.06)。
MFN、LVI和隐匿性淋巴结转移的高发生率表明,无论浸润深度、细胞类型、分化程度或BE范围如何,T1期食管癌患者均不适合采用ET。对于手术风险被认为过高的患者,ET可能具有价值。